Wednesday, July 9, 2025 7/9/2025

MagaVax Therapeutic Vaccine for Chronic HBV infection

Award Number: R43DK108606
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/23/2015
PERIOD OF PERFORMANCE END DATE: 08/31/2017

Group Awards By:

View Award Description

MagaVax Therapeutic Vaccine for Chronic HBV infection - ¿ DESCRIPTION (provided by applicant): Hepatitis B virus (HBV) infection, while preventable by routine vaccination, has already led to chronic HBV infection (CHB) in about 240 million people worldwide. Although antiviral drugs are available, these must be taken daily for life and are unaffordable for most of world's CHB population. Consequently, a therapeutic vaccine is needed that would stimulate sufficient immunity to control CHB. Because CD8+ T cells are both necessary and sufficient for clearing HBV from the liver, a therapeutic vaccine must elicit extremely strong anti-HBV CD8+ T cell responses. Such a vaccine must be strong enough to counter the PD-1/PD-L1 and CD4+ regulatory T cells (Tregs) that suppress effective anti-HBV CD8+ T cells in CHB. Mouse studies have shown that stimulation the CD40 receptor on dendritic cells can generate anti-HBV CD8+ T cells that are strong enough to overcome these suppressive mechanisms and lead to long- term HBV control. Consequently, this project aims to use a powerful form of soluble multi-trimer CD40 ligand (CD40L) in conjunction with the HBV Core antigen (HBcAg). The result is a fusion protein comprised of the multimerization scaffold (SPD) with Core antigen and CD40L (SPD- Core-CD40L). This is referred to as a Multi-Trimer Antigen Adjuvant Vaccine or "MagaVax." The Aims are to make the construct in an adenoviral vector, test its effectiveness at eliciting anti- HBV CD8+ T cells in mice in vivo, and show that i can activate human dendritic cells to present Core antigen to HBV-specific human CD8+ T cells in vitro. When these studies are complete, a MagaVax/HBV vaccine will be ready for further testing and development as treatment for CHB.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2018 ( Subtotal = $0 )
2018	2015	MULTIMERIC BIOTHERAPEUTICS, INC.	5580 LA JOLLA BLVD STE 76	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/26/2018	NEW	$0
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $223,899 )
2015	2015	MULTIMERIC BIOTHERAPEUTICS INC	5580 LA JOLLA BOULEVARD	LA JOLLA	CA	92037	SAN DIEGO	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/23/2015	NEW	$223,899
														Subtotal = $223,899

Grand Total All Awards = $223,899

Top

All Categories

About

Search

Reports

Data Submission

Award Information

MagaVax Therapeutic Vaccine for Chronic HBV infection

Award Number: R43DK108606

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/23/2015

PERIOD OF PERFORMANCE END DATE: 08/31/2017

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer